David Polinsky - 04 Aug 2026 Form 3 Insider Report for Ernexa Therapeutics Inc. (ERNA)

Reporting relationship: Director
Issuer ticker: ERNA
Reported as of: 04 Aug 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 27 Aug 2026, 19:52:45 UTC
Prior SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ David Polinsky

Key filing fact

David Polinsky filed Form 3 for Ernexa Therapeutics Inc. (ERNA) on 27 Aug 2026.

Key facts

This page summarizes David Polinsky's Form 3 filing for Ernexa Therapeutics Inc. (ERNA).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Aug 2026, 19:52.

Change

Previous filing in this sequence was filed on 23 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001726896 Primary reporting owner

Polinsky David

Relationship: Director
Address: C/O ERNEXA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE
Signature: /s/ David Polinsky
Signature date: 27 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ERNA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,000
Date: 04 Aug 2026
Ownership: Through Polo3K, LLC

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ERNA holding Derivative

Warrant

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 04 Aug 2026
Ownership: Through Polo3K, LLC
Underlying class: Common Stock
Underlying amount: 8,000
Exercise price: $17.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The warrant will expire on the earlier of (i) the five (5)-year anniversary of the original issuance date or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.